The two major glycoproteins on the surface of the respiratory syncytial virus (RSV) virion, the
attachment glycoprotein (G) and the fusion glycoprotein (F), control the initial phases of …

Highlights•There are multiple neutralizing antibody binding sites on F protein and at least
one on G protein.•The most potent neutralizing antibodies recognize sites exclusively on the …

The RSVPreF3-AS01 vaccine, containing the respiratory syncytial virus (RSV) prefusion F
protein and the AS01 adjuvant, was previously shown to boost neutralization responses …

Respiratory syncytial virus (RSV), the main cause of infant bronchiolitis, remains a major
unmet vaccine need despite more than 40 years of vaccine research. Vaccine candidates …

Respiratory syncytial virus (RSV) is a leading cause of infant mortality, and there are
currently no licensed vaccines to protect this vulnerable population. A comprehensive …

Respiratory syncytial virus (RSV) infection is the leading cause of hospitalization and infant
mortality under six months of age worldwide; therefore, the prevention of RSV infection in all …

For efficient prevention of viral infections and cross protection, simultaneous targeting of
multiple viral epitopes is a powerful strategy. Llama heavy chain antibody fragments (VHH) …

Respiratory syncytial virus (RSV) remains a major human pathogen, infecting the majority of
infants before age two and causing re-infection throughout life. Despite decades of RSV …

Highlights•X-ray crystal structures of prefusion and postfusion RSV F have been
determined.•Antibodies specific for the prefusion conformation are extremely potent.•Select …

Respiratory syncytial virus (RSV) is a major cause of pneumonia and bronchiolitis in infants
and elderly people. Currently there is no effective vaccine against RSV, but passive …